ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate

1 year ago 52

Hørsholm, Denmark, 16 April 2024 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS is pleased to announce the completion of the final report for the Good Laboratory Practice...

1. Homepage
2. Breast Cancer
3. ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate